25992 Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment
| Autor: | Jackson, J. Mark, Alexis, Andrew, Kucera, Kristine, Mendelsohn, Alan M., Rozzo, Stephen J., Gorelick, Joseph |
|---|---|
| Zdroj: | In Journal of the American Academy of Dermatology September 2021 85(3) Supplement:AB79-AB79 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect